NEW YORK, Nov. 09, 2015 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that results from on-going clinical trials evaluating TPI 287 for treatment of brain cancers will be presented at the upcoming 20th Annual Society for Neuro-Oncology Annual Scientific Meeting and Education Day in San Antonio, TX. Poster presentations will cover two company-sponsored studies evaluating TPI 287 plus bevacizumab (Avastin®) for treatment of patients with glioblastoma (GBM) recurring after front-line therapy, as well as an investigator-sponsored study evaluating TPI 287 in combination with radiation for treatment of tumor metastases to the brain.
Title: CB-017: A Phase 1/2 trial of bevacizumab plus TPI 287, a novel brain penetrable anti-microtubule agent, in patients with recurrent glioblastoma naïve to anti-angiogenic therapy
Date: Friday, November 20
Time: 7:30 – 9:30 PM CST
Abstract #: ATNT-08
Presenter: Samuel Goldlust, M.D., John Theurer Cancer Center, Hackensack, NJ
Title: CB-018: A Phase 2 trial of bevacizumab plus TPI 287, a novel brain penetrable anti-microtubule agent, in patients with recurrent glioblastoma following progression on anti-angiogenic therapy
Date: Friday, November 20
Time: 7:30 – 9:30 PM CST
Abstract #: ATCT-15
Presenter: Samuel Goldlust, M.D., John Theurer Cancer Center, Hackensack, NJ
Title: A Phase 1 study of TPI 287 concurrent with fractionated stereotactic radiotherapy in treatment of brain metastases from advanced breast and non-small cell lung cancer
Date: Friday, November 20
Time: 7:30 – 9:30 PM CST
Abstract #: ATNT-22
Presenter: Solmaz Sahebjam, M.D., Moffitt Cancer Center, Tampa, FL
About TPI 287
TPI 287 is a novel taxoid which binds to and stabilizes the assembly of microtubules similarly to commonly used taxanes, including paclitaxel (Taxol® and Abraxane®) and docetaxel (Taxotere®). In oncology treatment settings, microtubule stabilization by these agents leads to mitotic arrest and cancer cell death. TPI 287 has advantages over these taxanes due to its ability to circumvent common drug resistance mechanisms and its propensity to penetrate the central nervous system. Accordingly, TPI 287 has the potential to treat primary brain tumors and secondary brain metastases that are often shielded from systemic administration of taxanes and other chemotherapeutics. Microtubule stabilization by TPI 287 may also have potential for the treatment of neurologic disorders affected by tau protein pathology. These include tauopathies such as Alzheimer’s disease and orphan diseases, such as progressive supranuclear palsy, corticobasal degeneration, and frontotemporal dementia.
About Glioblastoma
Glioblastoma (GBM) is the most aggressive and common form of brain cancer. Five-year survival after diagnosis is about 5%. The Central Brain Tumor Registry estimates that about 23,180 primary malignant brain tumors cases will be diagnosed in the US in 2015, 46% of which will be GBM. Typical front-line treatments include stereotactic or whole brain radiotherapy plus temozolomide (Temodar®). Patients with recurrent disease are candidates for treatment with Avastin®, the last FDA approved agent for this disease.
About Metastases to the Brain
According to the American Society of Clinical Oncology, approximately 25% of all cancer patients develop secondary metastases to the brain, which translates into about 400,000 cases annually in the United States. Most commonly, brain metastases originate from lung cancers (50%), breast cancers (15-20%), and melanoma (10%). Fractionated stereotactic radiotherapy (FSRT) or whole brain radiotherapy (WBRT) remains the standard of care for treatment of patients with or without surgery. Mortality rates due to brain metastases are extremely high.
About Cortice Biosciences
Cortice Biosciences, Inc. is a clinical-stage drug development company pioneering novel therapies for the treatment of oncologic and neurologic disease indications with urgent unmet medical need. More information can be found at www.corticebiosciences.com.